Kiniksa Pharmaceuticals is a American stock, trading under the symbol KNSA-Q on the NASDAQ (KNSA). It is usually referred to as NASDAQ:KNSA or KNSA-Q
In the last year, there was no coverage of Kiniksa Pharmaceuticals published on Stockchase.
Kiniksa Pharmaceuticals was recommended as a Top Pick by on . Read the latest stock experts ratings for Kiniksa Pharmaceuticals.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
0 stock analysts on Stockchase covered Kiniksa Pharmaceuticals In the last year. It is a trending stock that is worth watching.
On 2023-03-24, Kiniksa Pharmaceuticals (KNSA-Q) stock closed at a price of $11.41.
KNSA is a pharmaceuticals company that focuses on autoimmune and anti inflammatory diseases and cancers. It is just now reaping the benefit of commercially released drug to help patients with inflammation of the sack around the heart. It trades at only 5x earnings, has a ROE of 63% and is a low beta stock (acts more independently from the underlying equity market). We recommend placing a stop-loss at $9, looking to achieve $22 — upside potential over 85%. Yield 0%
(Analysts’ price target is $22.00)